HUNTINGTON'S DISEASE NN 105 STAIR

SRX246: Safety, Tolerability, and Activity in Irritable Subjects with HD (STAIR)

WHAT IS THE PURPOSE OF THE STUDY?
To learn if a new investigational drug, SRX246, is a safe and effective drug for people with Huntington’s Disease (HD) who have symptoms of irritability or aggression. We will compare the study drug SRX246 to a placebo. Participants will have a 2 out of 3 chance of receiving the study drug (SRX246) and 1 out of 3 chance of receiving placebo.

AM I ELIGIBLE?
⇒ Must be at least 18 years old and have sufficient English skills for the questionnaires.
⇒ Must have a diagnosis of HD and experience symptoms of irritability or aggression.
⇒ You must have a study partner who is willing to participate in the study.

The study coordinator will provide you with a full list of requirements for participation.

STUDY VISITS
Study visits will include 1 screening visit, 1 baseline visit, 5 clinic visits and 2 telephone visits. If you participate in the study, you will be paid $50 and your study partner $30 for every clinic visit completed to assist with meals, travel and parking.

WHAT ARE THE BENEFITS OF THE STUDY?
You may or may not benefit from taking part in this research study.

For additional information, visit ClinicalTrials.gov, identifier number NCT02507284